Zai Lab Limited (HKG:9688)
22.90
+0.60 (2.69%)
May 13, 2025, 2:45 PM HKT
Zai Lab Revenue
Zai Lab had revenue of $106.49M USD in the quarter ending March 31, 2025, with 22.19% growth. This brings the company's revenue in the last twelve months to $418.33M, up 43.72% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$418.33M
Revenue Growth
+43.72%
P/S Ratio
7.68
Revenue / Employee
$223.82K
Employees
1,869
Market Cap
24.98B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 32.49B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
WuXi Biologics | 19.87B |
Innovent Biologics | 10.03B |
Alibaba Health Information Technology | 31.39B |
Akeso | 2.26B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Zai Lab News
- 1 day ago - Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates - Business Wire
- 4 days ago - Earnings Scheduled For May 8, 2025 - Benzinga
- 5 days ago - Zai Lab Q1 2025 Earnings Preview - Seeking Alpha
- 17 days ago - Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025 - Business Wire
- 18 days ago - NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025 - Benzinga
- 19 days ago - Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting - Business Wire
- 21 days ago - Zai Lab gets China's acceptance for label expansion of repotrectinib - Seeking Alpha